Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now

Pin to quick picksValirx Share News (VAL)

Share Price Information for Valirx (VAL)

London Stock Exchange
Share Price: 0.15
Bid: 0.14
Ask: 0.16
Change: 0.00 (0.00%)
Spread: 0.02 (14.29%)
Open: 0.15
High: 0.15
Low: 0.15
Yest. Close: 0.15
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

ValiRx secures 'substantial amendment' to VAL201 clinical trials

Thu, 20th Jun 2019 09:54

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

The AIM-traded firm said that, following the approval of the amendment, prostate cancer specialist Dr Mark Linch had been appointed as principal investigator to the clinical trial team at University College London Hospital (UCLH).

Dr Linch was an honorary senior lecturer at the University College London (UCL) Cancer Institute, where he was leading the uro-oncology biology group, and was also a consultant medical oncologist specialising in the treatment of prostate and bladder cancer at UCLH.

ValiRx confirmed that Dr Rebecca Kristeleit was continuing with the study as chief investigator.

It said that to date, the results generated by the trial - aided by sizable analytical method developments - had shown that safe toxicological limits could be significantly elevated and applied to much higher levels in humans than was suggested by the preclinical studies.

The approval given to relax the restrictions previously applied to the trial would mean that a more effective use of VAL201 could be achieved with respect to concentration and timing, and regarding increased flexibility in the administration of the drug, the board explained.

Additionally, it said the amendment relating to dosing strategies meant that - in light of accumulated clinical data - the company would be able to develop further protocols.

Those would be designed to evaluate a range of defined therapeutic approaches that were to be tested against each other, to determine the most effective approach in terms of disease management, cost effectiveness and patient welfare in further clinical trials.

The protocols would be the precursor to seeking approval to conduct trials aimed at gaining sufficient data to secure partnering and then marketing approval application.

ValiRx reported that the trial thus far had met all of its primary and secondary endpoints, with the safety and tolerability results continuing to be acceptable, and further evidence of the compound's positive effect in reducing the progress of prostate cancer witnessed.

The data from the trial was currently being collated for examination by independent third party experts.

ValiRx said the approval of the amendment further validated its clinical development throughout VAL201's first-in-human trial.

Further information connected to the data, and the results and findings from the trial, would form the basis of a report outlining the compound's clinical profile and behaviour, which would be published in due course.

"This substantial amendment has taken a lot of effort from the whole team both internal and by all our service providers to achieve," said ValiRx chief operating officer Dr George Morris.

"The most gratifying thing is that our original pre-clinical experimental data has held up well and been vindicated throughout the whole of this first-in-human trial.

"Now, as the trial is delivering an extensive and positive output, it is also providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which we will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved."

More News

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

10 Sep 19 13:45

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

1 Aug 19 12:01

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

23 Jul 19 16:25

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

26 Jun 19 14:30

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

26 Jun 19 10:53

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

20 Jun 19 09:54

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

13 Jun 19 11:07

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

10 Jun 19 09:50

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

5 Jun 19 10:54

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

31 May 19 12:04

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

29 May 19 10:41

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

29 May 19 10:19

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

2 May 19 15:21

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

2 May 19 09:51

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

26 Apr 19 14:54

Login to your account

Don't have an account? Click here to register.